Michael K Keng
Overview
Explore the profile of Michael K Keng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Manero G, Kazmierczak M, Wierzbowska A, Fong C, Keng M, Ballinari G, et al.
Leuk Res
. 2024 Mar;
140:107480.
PMID: 38499457
Non-intensive therapies such as the hypomethylating agent (HMA) azacitidine (AZA) have been used in patients with AML ineligible for intensive induction chemotherapy (IC) or stem cell transplant due to advanced...
2.
Robinson E, Keng M, Thomas T, Cox H, Park S, Mathers A
Open Forum Infect Dis
. 2022 Nov;
9(11):ofac521.
PMID: 36408469
Background: Limited data exist to guide blood culture ordering in persistent febrile neutropenia (FN), resulting in substantial variation in practice. Unnecessary repeat blood cultures have been associated with patient harm...
3.
Ung J, Tan S, Fox T, Shaw J, Vass L, Costa-Pinheiro P, et al.
Blood Rev
. 2022 Apr;
55:100950.
PMID: 35487785
Acute myeloid leukemia (AML) is an aggressive, heterogenous malignancy characterized by clonal expansion of bone marrow-derived myeloid progenitor cells. While our current understanding of the molecular and genomic landscape of...
4.
Riley D, Schlefman J, Vitzthum Von Eckstaedt V H, Morris A, Keng M, El Chaer F
Curr Hematol Malig Rep
. 2021 May;
16(3):314-324.
PMID: 33978914
Purpose Of Review: The incorporation of pegaspargase in chemotherapy regimens has significantly improved the prognosis of ALL in adults. However, pegaspargase use poses many challenges due to its unique toxicity...
5.
Isaac K, Reed D, Desai R, Williams E, Balkrishnan R, Keng M, et al.
Cancer Rep (Hoboken)
. 2021 Mar;
4(4):e1354.
PMID: 33751859
Background: Acute myeloid leukemia, the most common acute leukemia in adults, has a poor overall survival. Studies have suggested that certain socioeconomic factors such as living in a rural or...
6.
Wages N, Reed D, Keng M, Conaway M, Petroni G
Clin Trials
. 2021 Jan;
18(3):314-323.
PMID: 33426919
Background/aims: This article describes the proposed design of a phase I study evaluating the safety of ceramide nanoliposome and vinblastine among an initial set of 19 possible dose combinations in...
7.
Reed D, Sen J, Pierce E, Elsarrag R, Keng M
J Oncol Pharm Pract
. 2020 Apr;
26(5):1200-1212.
PMID: 32338136
Acute myeloid leukemia has recently undergone a significant transition into identifying and successfully inhibiting driver mutations leading to disease. One of the most common mutations in acute myeloid leukemia involves...
8.
Schaeffer C, Moran T, Keng M, Bateman H, DeGeorge Jr B
Ann Plast Surg
. 2020 Mar;
85(1):29-32.
PMID: 32149843
Septic, inflammatory, or crystal-induced arthritis are common etiologies of wrist pain without antecedent trauma associated with pain, loss of motion, swelling, redness, and warmth. In this report, we detail the...
9.
Reed D, Elsarrag R, Morris A, Keng M
Cancer Manag Res
. 2019 Oct;
11:8073-8080.
PMID: 31564968
Recently there has been a significant progression in the understanding of molecular mutations driving biochemical and cellular signaling changes leading to survival and proliferation of leukemia cells in patients with...
10.
Reed D, Pierce E, Sen J, Keng M
Cancer Manag Res
. 2019 Sep;
11:8065-8072.
PMID: 31507329
Purpose: Intravenous (IV) sodium bicarbonate is typically used in alkalization regimens for the safe use of the chemotherapeutic agent high-dose methotrexate (HDMTX). Urine parameters including urine output and pH are...